Allogene Therapeutics Inc

ALLO

Equity

ISIN null / Valor 43756548

NASDAQ (2026-02-24)

USD 2.29+10.1%

Allogene Therapeutics Inc
UMushroom community rating:

3.00 3 votes No rating yet

NegativeNeutralPositive

About company

Allogene Therapeutics Inc is a clinical-stage biotechnology firm focused on the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer treatment. The company operates at the forefront of cell therapy research, leveraging a comprehensive, in-house team for the discovery, translational research, development, and manufacturing of cell therapies. Allogene has established significant partnerships to enhance its technological capabilities and product pipeline. This includes a collaboration with Antion for miRNA technology to improve immune evasion strategies for AlloCAR T™ candidates, granting Allogene exclusive commercialization rights for certain targets. Additionally, the company has an exclusive agreement with Notch Therapeutics to develop induced pluripotent stem cell (iPSC) AlloCAR™ products for various cancers, utilizing Notch’s Engineered Thymic Niche (ETN) platform. Allogene is also co-developing ALLO-501 and ALLO-501A, anti-CD19 therapies, in partnership with Servier, based on a license from Cellectis, with exclusive rights in the U.S. and an option for global rights. These strategic collaborations underscore Allogene's commitment to advancing its portfolio of cancer therapies through innovative research and development initiatives.

Summarized from source with an LLMView SourceSector: Healthcare